

04 September 2025

Impact of GST rate rationalization on the Pharma sector

GST reduction on medicines and medical devices for affordable healthcare

**Suresh Nair***Tax Partner, EY India*

The GST Council's tax reforms in the pharmaceutical sector marks a significant step toward affordable healthcare. By reducing GST on all medicines from 12% to 5% and exempting 36 critical lifesaving drugs for ailments such as cancer and rare disorders, the reform substantially lowers patient costs and improves access to vital treatments. Lowering GST on medical devices from 18% or 12% to 5% further enhances the affordability of essential healthcare. In addition, GST on pharma job work services has been reduced from 12% to 5%. This people-centric reform promotes equitable healthcare access, strengthens public health and industry growth, and reinforces India's position as a global pharma leader.

Key changes:

- Reduction of GST from 12% to nil on 33 lifesaving drugs and medicines, and from 5% to nil on 3 lifesaving drugs and medicines used for the treatment of cancer, rare diseases, and other severe chronic conditions
- Reduction of GST on all other drugs and medicines from 12% to 5%
- Reduction of GST from 18% to 5% on various medical apparatus and devices used for medical, surgical, dental or veterinary purposes, or for physical or chemical analysis
- Reduction of GST from 12% to 5% on various medical equipment and supplies, such as wadding, gauze, bandages, diagnostic kits and reagents, blood glucose monitoring systems (glucometers), and other medical devices
- Reduction in GST from 12% to 5% for job work services in relation to goods falling under Chapter 30

A detailed list of the proposed GST rate changes in the pharma sector has been covered separately in the Annexure to this alert

Impact analysis

Industry impact:

- **Reduced GST on all drugs and medicines:** Reduction in GST rates on all drugs and medicines from 12% to 5%, and granting a NIL rate to 36 lifesaving drugs and medicines for conditions such as cancer, rare diseases, and other chronic illnesses, will significantly reduce patient expenses and improve access to essential therapies, thereby advancing affordable healthcare.
- **Lower cost of medical equipment and devices:** Reduction in GST rates from 18% or 12% to 5% on various medical equipment and devices will lower costs for hospitals and diagnostic centers, ultimately benefiting patients.
- **Increase in inverted duty structure:** GST rates on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), typically taxed at 18%, have not been reduced. The reduction in GST rates on all drugs and medicines to 5% intensifies tax inversion (inputs taxed higher than outputs) for pharma companies, leading to higher accumulation of input tax credit (ITC) and potential working capital strain for manufacturers, despite the provision for a 90% provisional refund of ITC on account of the inverted duty structure under GST law.
- **Impact on inventory:** Inventory purchased at old rates may need repricing or discounting, affecting margins.
- **Impact on incentives:** Companies availing state-level incentives (computed on net SGST paid in cash) and those claiming the Budgetary Support Scheme (58% of IGST or 29% of CGST paid in cash) may see a reduction in incentive amounts due to lower tax outflows.

Highlights

GST reduction on 36 lifesaving drugs and medicines used for treatment of cancer, rare diseases and other severe chronic conditions

12%
/5%  NIL

Before Now

GST reduction on all formulations (excl. above identified drugs) and on job work services for pharma products

12%  5%

Before Now



Impact analysis

Consumer impact

- Patients are expected to directly benefit from the reduced GST rates on drugs, medicines, medical devices and equipment. The reduction in GST rates from 12% to 5% on all drugs and medicines, and to NIL on lifesaving drugs and medicines for conditions such as cancer, rare diseases, and other severe chronic illnesses, coupled with the cut in GST rates on various medical equipment and devices, will improve the affordability and accessibility of healthcare for patients at large.

Way forward:

- **Ensuring system readiness:** Update ERP and tax systems to incorporate revised GST rates.
- **Pricing strategy:** Reassess product pricing, MRP setting, and margin planning across revised rate slabs to reflect tax reductions.
- **Trade alignment:** Restructure pricing policies, align with distributors/trade partners, renegotiate contracts, and ensure timely communication on transitional aspects to minimize supply chain disruptions.
- **Government advocacy:** Explore representation of key issues including:
 - Align the GST rate for APIs/ KSM with the GST rate of formulations
 - Allowing a refund of inverted duty on capital goods and input services.
 - Extending the inverted duty refund to traders facing ITC accumulation due to rate changes.
- **Transitional planning:** Identify old stock, plan credit notes/discounts to clear inventory, and other regulatory requirements, as applicable.
- **Considerations for importers of pharma products and medical devices:** Assess the risk of ITC accumulation for imported consignments in transit or on-hand stock, and consider mitigation measures such as bonded warehouse imports, subject to business and commercial feasibility.

Highlights

**Relief in the Healthcare sector:
GST reduction for
thermometers,
medical grade
oxygen, all diagnostic
kits and reagents,
Glucometers and test
strips, and corrective
spectacles**

**18/
12% » 5%**

Before **Now**



Annexure

GST rate changes proposed as per press release issued on 3 September 2025

- List of drugs and medicines under Chapter 30 on which the GST rate is proposed to be reduced from 5% to nil

S. no.	Description of goods
1	Agalsidase Beta
2	Imiglucerase
3	Eptacog alfa activated recombinant coagulation factor VIIa

- List of drugs and medicines under Chapter 30 on which the GST rate is proposed to be reduced from 12% to nil

S. no.	Description of goods	S no	Description of goods
1	Onasemnogene abeparvovec	18	Rurioctocog Alpha Pegol
2	Asciminib	19	Idursulphatase
3	Mepolizumab	20	Alglucosidase Alfa
4	Pegylated Liposomal Irinotecan	21	Laronidase
5	Daratumumab	22	Olipudase Alfa
6	Daratumumab subcutaneous	23	Tepotinib
7	Teclistamab	24	Avelumab
8	Amivantamab	25	Emicizumab
9	Alectinib	26	Belumosudil
10	Risdiplam	27	Miglustat
11	Obinutuzumab	28	Velmanase Alfa
12	Polatuzumab vedotin	29	Alirocumab
13	Entrectinib	30	Evolocumab
14	Atezolizumab	31	Cystamine Bitartrate
15	Spesolimab	32	CI-Inhibitor injection
16	Velaglucerase Alpha	33	Inclisiran
17	Agalsidase Alfa		



Annexure

- List of pharmaceuticals products and medical devices on which the GST rate is proposed to be reduced from 12% to 5% (1 of 3)

S. no.	Chapter / heading / sub-heading / tariff item	Description of goods
1.	28	Anesthetics
2.	28	Potassium Iodate
3.	28	Steam
4.	2801 20	Iodine
5.	2804 40 10	Medical grade oxygen
6.	2847	Medicinal grade hydrogen peroxide
7.	30	All Drugs and medicines including: <ul style="list-style-type: none">Fluticasone Furoate + Umeclidinium + Vilanterol FF/UMEC/VIBrentuximab VedotinOcrelizumabPertuzumabPertuzumab + trastuzumabFaricimab
8.	3001	Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included



Annexure

- List of pharmaceuticals products and medical devices on which GST rate is proposed to be reduced from 12% to 5% (2 of 3)

S. no.	Chapter / heading / sub-heading / tariff item	Description of goods
9.	3002	Animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; toxins, cultures of micro-organisms (excluding yeasts) and similar products
10.	3003	Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, including Ayurvedic, Unani, Siddha, homoeopathic or Bio-chemic systems medicaments
11.	3004	Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale, including Ayurvedic, Unani, homoeopathic siddha or Bio-chemic systems medicaments, put up for retail sale
12.	3005	Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes
13.	3006	Pharmaceutical goods specified in Note 4 to this Chapter [i.e., Sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure; sterile laminaria and sterile laminaria tents; sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable; Waste pharmaceuticals] [other than contraceptives and Ostomy appliances]
14.	3822	All diagnostic kits and reagents
15.	4015	Surgical rubber gloves or medical examination rubber glove
16.	90 or any other Chapter	Blood glucose monitoring system (Glucometer) and test strips
17.	90 or any other Chapter	Patent Ductus Arteriousus / Atrial Septal Defect occlusion device



Annexure

- List of pharmaceuticals products and medical devices on which GST rate is proposed to be reduced from 12% to 5% (3 of 3)

S. no.	Chapter / heading / sub-heading / tariff item	Description of goods
18.	9004	Spectacles and goggles for correcting vision
19.	9018	Instruments and appliances used in medical, surgical, dental or veterinary sciences, including scintigraphic apparatus, other electro-medical apparatus and sight-testing instruments
20.	9019	Mechano-therapy appliances; massage apparatus; psychological aptitude-testing apparatus; ozone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic respiration apparatus
21.	9020	Other breathing appliances and gas masks, excluding protective masks having neither mechanical parts nor replaceable filters
22.	9022	Apparatus based on the use of X-rays or of alpha, beta or gamma radiations, for medical, surgical, dental or veterinary uses, including radiography or radiotherapy apparatus, X-ray tubes and other X-ray generators, high tension generators, control panels and desks, screens, examinations or treatment tables, chairs and the light
23.	9804	Other drugs and medicines intended for personal use



Annexure

- List of medical devices on which GST rate is proposed to be reduced from 18% to 5%

S. no.	Chapter / heading / sub-heading / tariff item	Description of goods
1.	9025	Thermometers for medical, surgical, dental or veterinary usage
2.	9027	Instruments and apparatus for medical, surgical, dental or veterinary uses for physical or chemical analysis

Our Offices

Ahmedabad

22nd Floor, B Wing,
Privilon
Ambli BRT Road, Behind
Iskcon Temple
Off SG Highway,
Ahmedabad - 380 059
Tel:+ 91 79 6608 3800

8th Floor, Building No. 14A
Block 14, Zone 1
Brigade International
Financial Centre
GIFT City SEZ
Gandhinagar - 382 355,
Gujarat
Tel + 91 79 6608 3800

Bengaluru

12th & 13th Floor
"UB City", Canberra Block
No.24 Vittal Malliya Road
Bengaluru - 560 001
Tel:+ 91 80 6727 5000

Ground & 1st Floor
11, 'A' wing
Divyasree Chambers
Langford Town
Bengaluru - 560 025
Tel:+ 91 80 6727 5000

3rd & 4th Floor
MARKSQUARE
#61, St. Mark's Road
Shantala Nagar
Bengaluru - 560 001
Tel:+ 91 80 6727 5000

1st & 8th Floor, Tower A
Prestige Shantiniketan
Mahadevapura Post
Whitefield, Bengaluru -
560 048
Tel:+ 91 80 6727 5000

Bhubaneswar

8th Floor, O-Hub, Tower A
Chandaka SEZ,
Bhubaneswar
Odisha - 751024
Tel: + 91 674 274 4490

Chandigarh

Elante offices, Unit No. B-
613 & 614
6th Floor, Plot No- 178-
178A
Industrial & Business
Park, Phase-I
Chandigarh - 160 002
Tel:+ 91 172 6717800

Chennai

6th & 7th Floor, A Block,
Tidel Park, No.4, Rajiv
Gandhi Salai
Taramani, Chennai - 600
113
Tel:+ 91 44 6654 8100

Delhi NCR

Aikyam
Ground Floor
67, Institutional Area
Sector 44, Gurugram -
122 003
Haryana
Tel: + 91 124 443 4000

3rd & 6th Floor,
Worldmark-1
IGI Airport Hospitality
District
Aerocity, New Delhi - 110
037
Tel: + 91 11 4731 8000

4th & 5th Floor, Plot No
2B
Tower 2, Sector 126
Gautam Budh Nagar, U.P.
Noida - 201 304
Tel:+ 91 120 671 7000

Hyderabad

THE SKYVIEW 10
18th Floor, "SOUTH
LOBBY"
Survey No 83/1,
Raidurgam
Hyderabad - 500 032
Tel:+ 91 40 6736 2000

Jaipur

9th floor, Jewel of India
Horizon Tower, JLN Marg
Opp Jaipur Stock
Exchange
Jaipur, Rajasthan -
302018

Kochi

9th Floor, ABAD Nucleus
NH-49, Maradu PO
Kochi - 682 304
Tel:+ 91 484 433 4000

Kolkata

22 Camac Street
3rd Floor, Block 'C'
Kolkata - 700 016
Tel:+ 91 33 6615 3400

6th floor, Sector V,
Building Omega, Bengal
Intelligent Park, Salt Lake
Electronics Complex,
Bidhan Nagar
Kolkata - 700 091
Tel: + 91 33 6615 3400

Mumbai

14th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (W),
Mumbai - 400 028
Tel:+ 91 22 6192 0000

5th Floor, Block B-2
Nirlon Knowledge Park
Off. Western Express
Highway
Goregaon (E)
Mumbai - 400 063
Tel:+ 91 22 6192 0000

3rd Floor, Unit No.301
Building No.1, Mindspace-
Gigaplex
IT Park, MIDC, Plot No. IT-5
Airoli Knowledge Park
Airoli West,
Navi Mumbai - 400 708
Tel: + 91 22 6192 0003

18th Floor, Altimus
Pandurang Budhkar Marg
Worli, Mumbai - 400 018
Tel: + 91 22 6192 0503

Pune

C-401, 4th Floor
Panchshil Tech Park,
Yerwada
(Near Don Bosco School)
Pune - 411 006
Tel: + 91 20 4912 6000

10th Floor, Smartworks
M-Agile, Pan Card Club Road
Baner, Pune - 411 045
Tel: + 91 20 4912 6800

Ernst & Young LLP

EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EYG member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is one of the Indian client serving member firms of EYGM Limited. For more information about our organization, please visit www.ey.com/en_in.

Ernst & Young LLP is a Limited Liability Partnership, registered under the Limited Liability Partnership Act, 2008 in India, having its registered office at Ground Floor, Plot No. 67, Institutional Area, Sector - 44, Gurugram - 122 003, Haryana, India.

© 2025 Ernst & Young LLP. Published in India.
All Rights Reserved.

This publication contains information in summary form and is therefore intended for general guidance only. It is not intended to be a substitute for detailed research or the exercise of professional judgment. Neither EYGM Limited nor any other member of the global Ernst & Young organization can accept any responsibility for loss occasioned to any person acting or refraining from action as a result of any material in this publication. On any specific matter, reference should be made to the appropriate advisor.

ey.com/en_in

